Fairmount Funds Management LLC
Registered adviserRegulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
| Rosters | Regulatory AUM | Main clients |
|---|---|---|
| Sep 2026 to Oct 2026 | $5,799,058,000 | Pooled investment vehicles (100%) |
| Aug 2026 | $5,799,058,000 | Pooled investment vehicles (100%) |
| Apr 2026 to Jul 2026 | $5,799,058,000 | Pooled investment vehicles (100%) |
| Mar 2026 | $3,168,724,000 | Pooled investment vehicles (100%) |
| Apr 2025 to Feb 2026 | $3,168,724,000 | Pooled investment vehicles (100%) |
| Mar 2025 | $2,276,508,000 | Pooled investment vehicles (100%) |
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 99.1%; sector active share 90.6% against the combined 13F book's sector weights.
Over time 26 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
12 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $1,512,967,792 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| VRDN | Viridian Therapeutics, Inc.\DE | +1,176,470 | 5,090,928 | $93,520,347 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reducedNew Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| FTH | Faeth Therapeutics, Inc. | 722,020 | $18,050,500 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | 4,018,101 | $202,673,014 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
Held | 3,705,262 | $352,629,784 | 23.31% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
Held | 2,537,191 | $247,325,378 | 16.35% | |
| DMRA |
Damora Therapeutics, Inc.
Healthcare
|
Held | 8,713,000 | $226,625,130 | 14.98% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Held | 5,503,418 | $212,982,276 | 14.08% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
Held | 4,553,494 | $101,178,636 | 6.69% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Held | 1,855,644 | $94,173,933 | 6.22% | |
| VRDN |
Viridian Therapeutics, Inc.\DE
Healthcare
|
Added | 5,090,928 | $93,520,347 | 6.18% | |
| ZBIO |
Zenas BioPharma, Inc.
Healthcare
|
Held | 2,359,025 | $59,872,054 | 3.96% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
Held | 2,747,866 | $49,461,588 | 3.27% | |
|
|
Held | 298,647 | $39,639,416 | 2.62% | ||
| FTH |
Faeth Therapeutics, Inc.
Healthcare
|
NEW | 722,020 | $18,050,500 | 1.19% | |
| IKT |
Inhibikase Therapeutics, Inc.
Healthcare
|
Held | 8,625,000 | $17,508,750 | 1.16% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.